Article Text

Download PDFPDF

Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint
  1. Luke S Howard
  1. Correspondence to Dr Luke S Howard, National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0HS, UK; l.howard{at}imperial.ac.uk

Statistics from Altmetric.com

If we had robust evidence one way or the other to inform us on the use of thrombolytics in submassive pulmonary embolus (PE), we would not need this debate. But, we do not and, so, we do. The stakes are considered high both in favour and against thromobolysing submassive PE, so we cannot brush the debate under the carpet while we await the evidence. It is accepted that high-risk/massive PE, defined as haemodynamic instability, merits aggressive treatment due to unacceptable mortality, which outweighs the risk of haemorrhage. At the other end of the spectrum, patients with low-risk PE do not, such that they may even be treated as outpatients.

This leaves a grey area in between. When faced with a patient with a large thrombus load with a right ventricle (RV) that is dilated and pressure-loaded, but who is normotensive, as the attending clinician, we know they are at increased risk of death and long-term complications, such as chronic thromboembolic pulmonary hypertension (CTEPH).1 ,2 We may fall back on the Hippocratic Oath to ‘first, do no harm’, but the fuller translation reads ‘I will use treatments for the benefit of the ill in accordance with my ability and my judgment, but from what is to their harm and injustice I will keep them’. Thus, rather than hide behind a lack of evidence, we must review what we have and come to a balanced decision, and justify it.

In proposing the argument that submassive PE should be treated with thrombolysis, we must first accept that direct mortality due to the PE itself, not confounding conditions, remains unacceptably high with anticoagulation alone. A more aggressive strategy is required. As long as the benefits of thrombolysis outweigh the risks, then thrombolysis offers the best currently available approach. When …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Pulmonary vasculature
    David Jiménez José Luis Lobo Manuel Monreal Lisa Moores Mikel Oribe Manuel Barrón Remedios Otero Dolores Nauffal Ramón Rabuñal Reina Valle Carmen Navarro Consolación Rodríguez-Matute Celso Álvarez Francisco Conget Fernando Uresandi Drahomir A Aujesky Roger D Yusen on behalf of the PROTECT investigators Celso Álvarez Jose María Abaitúa Víctor Abraira Ángel Alonso Luis Javier Alonso Aitor Ballaz Marta Ballester Manuel Barrón Sem Briongos Eva Castañer Olalla Castro Francisco Conget José María Cuesta Teresa Elías Vicente Gómez Ignacio Gallego Mariano González Luis Gorospe Eva Guillaumet Concepción Iglesias David Jiménez Francisco López Mónica López María Lladó José Luis Lobo Pilar Lucio Jesús Marín María Martín Manuel Monreal Alfonso Muriel Dolores Nauffal Carmen Navarro Mikel Oribe Ana Osa Remedios Otero José Pamies María Victoria Piret Delfina Pozo Amador Prieto Ramón Rabuñal Consolación Rodríguez Nuria Rodríguez Carmen Rodrigo Miguel Ángel Santolaria Pilar Serrano Ana Testa Fernando Uresandi Reina Valle Sonia Velasco Agustina Vicente Jorge Vivancos Roger D. Yusen Javier Zamora Vanesa Zorrilla José Luis de Benito José Manuel del Rey
  • Pulmonary vasculature
    Nika Skoro-Sajer Gabriel Marta Christian Gerges Gerald Hlavin Patrick Nierlich Shahrokh Taghavi Roela Sadushi-Kolici Walter Klepetko Irene Marthe Lang
  • Editorial
    A John Simpson
  • Airwaves
    Andrew Bush Ian Pavord